EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adverse cardiovascular events are common during dexmedetomidine administration in neonates and infants during intensive care

Miikka Tervonen iD, Johanna Cajanus, Merja Kallio iD, Heikki Huhtamäki, Tytti Pokka, Outi Peltoniemi

Acta Paediatrica · 2023

DOI: 10.1111/apa.16933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Paediatrica, 2023. Verfasst von Miikka Tervonen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland. Hauptthemen laut MEDLINE: Dexmedetomidine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lastentautien Tutkimussäätiö, Stiftelsen Alma och K. A. Snellman Säätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study aimed to assess the safety of a commonly used sedative, dexmedetomidine in neonates and infants during intensive care.

Methods

A retrospective cohort study was conducted in the paediatric intensive care unit at Oulu University Hospital. The study population consisted of all children from birth up to 6 months of age who received dexmedetomidine during 2010–2016. Adverse cardiovascular outcomes were defined as abnormal heart rates or blood pressure values according to the Paediatric Early Warning Score.

Results

Of the 172 infants, 56% had congenital malformation, and 48% had undergone surgery. Neonates and 1–3‐month‐olds experienced bradycardia (86% vs. 73% in 1–3‐month‐olds and 50% in 3–6‐month‐olds, p = 0.001) and severe bradycardia (17% vs. 14% in 1–3‐month‐olds and 0% in 3–6‐month‐olds, p = 0.005) more often than older patients. The median maximum rate of dexmedetomidine infusion was 0.86 μg/kg/h (IQR = 0.60–1.71 μg/kg/h). A dose‐dependent increase in bradycardia and severe hypotension was found. Adverse cardiovascular events were managed with additional fluid boluses and discontinuation of the infusion.

Conclusion

Adverse cardiovascular events were common during dexmedetomidine administration in neonates and infants. Lower dexmedetomidine doses may be required in sedating neonates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineInfant, NewbornChildHumansInfantBradycardiaRetrospective StudiesHypnotics and SedativesCritical Care

Stichwörter der Autor:innen

critical caredexmedetomidineinfantspain managementsedation

Substanzen

DexmedetomidineHypnotics and Sedatives

Autor:innen und Institutionen

  • Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland.
  • PEDEGO Research Unit and Medical Research Center Oulu, University of Oulu, Oulu, Finland.

ORCID-Profile: Miikka Tervonen, Merja Kallio

Förderung

  • Lastentautien Tutkimussäätiö
  • Stiftelsen Alma och K. A. Snellman Säätiö

Zitieren

APA

Tervonen, M., Cajanus, J., Kallio, M., Huhtamäki, H., Pokka, T., & Peltoniemi, O. (2023). Adverse cardiovascular events are common during dexmedetomidine administration in neonates and infants during intensive care. Acta Paediatrica. https://doi.org/10.1111/apa.16933

Vancouver

Tervonen M, Cajanus J, Kallio M, Huhtamäki H, Pokka T, Peltoniemi O. Adverse cardiovascular events are common during dexmedetomidine administration in neonates and infants during intensive care. Acta Paediatrica. 2023. doi:10.1111/apa.16933

BibTeX
@article{Tervonen2023,
  author = {Tervonen, Miikka and Cajanus, Johanna and Kallio, Merja and Huhtamäki, Heikki and Pokka, Tytti and Peltoniemi, Outi},
  title = {Adverse cardiovascular events are common during dexmedetomidine administration in neonates and infants during intensive care},
  journal = {Acta Paediatrica},
  year = {2023},
  doi = {10.1111/apa.16933}
}
Kostenlos starten →